[go: up one dir, main page]

MA33582B1 - Anticorps contre l'ectodomaine de erbb3 et leurs utilisations - Google Patents

Anticorps contre l'ectodomaine de erbb3 et leurs utilisations

Info

Publication number
MA33582B1
MA33582B1 MA34684A MA34684A MA33582B1 MA 33582 B1 MA33582 B1 MA 33582B1 MA 34684 A MA34684 A MA 34684A MA 34684 A MA34684 A MA 34684A MA 33582 B1 MA33582 B1 MA 33582B1
Authority
MA
Morocco
Prior art keywords
erbb3
antibodies
antigen
binding fragments
receptor
Prior art date
Application number
MA34684A
Other languages
Arabic (ar)
English (en)
Inventor
Birgit Schoeberl
Ulrik Nielsen
Michael Feldhaus
Original Assignee
Merrimack Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43607614&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA33582(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merrimack Pharmaceuticals Inc filed Critical Merrimack Pharmaceuticals Inc
Publication of MA33582B1 publication Critical patent/MA33582B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention a pour objet une nouvelle classe d'anticorps et leurs fragments de liaison à l'antigène qui se lient au domaine extracellulaire du récepteur erbb3 et inhibent différentes fonctions de erbb3. Par exemple, les anticorps et les fragments de liaison à l'antigène selon la présente invention sont capables de se lier au récepteur désigné erbb3 et d'inhiber la phosphorylation du récepteur médiée par un ligand de type egf. De tels anticorps et leurs fragments de liaison à l'antigène ont la caractéristique utile d'inhiber la prolifération des cellules cancéreuses exprimant erbb3.
MA34684A 2009-08-21 2012-03-12 Anticorps contre l'ectodomaine de erbb3 et leurs utilisations MA33582B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US23579909P 2009-08-21 2009-08-21
PCT/US2010/046364 WO2011022727A2 (fr) 2009-08-21 2010-08-23 Anticorps contre l’ectodomaine de erbb3 et leurs utilisations

Publications (1)

Publication Number Publication Date
MA33582B1 true MA33582B1 (fr) 2012-09-01

Family

ID=43607614

Family Applications (1)

Application Number Title Priority Date Filing Date
MA34684A MA33582B1 (fr) 2009-08-21 2012-03-12 Anticorps contre l'ectodomaine de erbb3 et leurs utilisations

Country Status (21)

Country Link
EP (1) EP2467164A2 (fr)
JP (1) JP5752687B2 (fr)
KR (1) KR20120059568A (fr)
CN (1) CN103002912A (fr)
AU (1) AU2010284018C1 (fr)
BR (1) BR112012003809A2 (fr)
CA (1) CA2771744A1 (fr)
CR (1) CR20120108A (fr)
DO (1) DOP2012000044A (fr)
EA (1) EA201200195A1 (fr)
EC (1) ECSP12011740A (fr)
IL (1) IL218097A0 (fr)
IN (1) IN2012DN01518A (fr)
MA (1) MA33582B1 (fr)
MX (1) MX336091B (fr)
NI (1) NI201200027A (fr)
PE (1) PE20121585A1 (fr)
SG (1) SG178509A1 (fr)
TN (1) TN2012000057A1 (fr)
WO (1) WO2011022727A2 (fr)
ZA (1) ZA201201195B (fr)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2631727T3 (es) 2007-02-16 2017-09-04 Merrimack Pharmaceuticals, Inc. Anticuerpos contra el ErbB3 y usos de los mismos
CN105999263B (zh) * 2009-11-13 2021-06-29 第一三共欧洲有限公司 用于治疗或预防人表皮生长因子受体-3(her-3)相关疾病的材料和方法
CN102822201B (zh) 2009-12-22 2014-09-24 罗切格利卡特公司 抗her3抗体及其用途
EP2544680B1 (fr) 2010-03-11 2015-01-14 Merrimack Pharmaceuticals, Inc. Utilisation d'inhibiteurs d'erbb3 dans le traitement de cancers du sein triples négatifs
BR112012025730B1 (pt) 2010-04-09 2020-12-08 Aveo Pharmaceuticals, Inc anticorpo isolado que se liga ao erbb3 humano, seus usos, seu processo de produção e vetor de expressão
BR112013004012B1 (pt) 2010-08-20 2021-03-23 Novartis Ag Anticorpo monoclonal isolado ou fragmento de ligação ao antígeno do mesmo ao receptor her3, seu uso e composição farmacêutica
TW201302793A (zh) 2010-09-03 2013-01-16 Glaxo Group Ltd 新穎之抗原結合蛋白
IT1402149B1 (it) * 2010-10-04 2013-08-28 Ist Fisioterap Ospitalroma Uso di un fosfopeptide in grado di bloccare l interazione her3/p85 per il trattamento dei tumori iperesprimenti her2.
MX348637B (es) 2010-11-01 2017-06-22 Symphogen As Anticuerpos y composiciones anti-her3.
KR101517320B1 (ko) 2011-04-19 2015-05-28 메리맥 파마슈티컬즈, 인크. 단일특이적 및 이중특이적 항-igf-1r 및 항 erbb3 항체
AU2012274461A1 (en) 2011-06-20 2014-01-16 Kyowa Hakko Kirin Co., Ltd. Anti-erbB3 antibody
MX357391B (es) 2011-09-30 2018-07-06 Regeneron Pharma Anticuerpos anti-erbb3 y usos de los mismos.
US9273143B2 (en) 2011-09-30 2016-03-01 Regeneron Pharmaceuticals, Inc. Methods and compositions comprising a combination of an anti-ErbB3 antibody and an anti-EGFR antibody
CN103959065B (zh) 2011-10-06 2018-07-17 Aveo制药公司 预测肿瘤对抗erbb3抗体的应答
EP2788377B1 (fr) * 2011-11-09 2019-01-23 The UAB Research Foundation Anticorps her3 et utilisations de ceux-ci
WO2013084147A2 (fr) 2011-12-05 2013-06-13 Novartis Ag Anticorps dirigés contre le récepteur 3 du facteur de croissance épidermique (her3)
WO2013124297A1 (fr) * 2012-02-22 2013-08-29 U3 Pharma Gmbh Composition d'une protéine de liaison d'hb-egf et d'un inhibiteur de l'egfr
US9180185B2 (en) 2013-01-11 2015-11-10 Hoffman-La Roche Inc. Combination therapy of anti-HER3 antibodies
US20160232293A1 (en) * 2013-10-17 2016-08-11 Sanford-Burnham Medical Research Institute Drug sensitivity biomarkers and methods of identifying and using drug sensitivity biomarkers
WO2015100459A2 (fr) 2013-12-27 2015-07-02 Merrimack Pharmaceuticals, Inc. Profils de biomarqueur pour prédire les résultats d'une thérapie cancéreuse utilisant des inhibiteurs d'erbb3 et/ou des chimiothérapies
CA2941030C (fr) 2014-02-28 2025-05-13 Merus N.V. Anticorps qui se lient à l'egfr et à l'erbb3
CN110642952B (zh) * 2014-08-14 2021-05-25 上海生物制品研究所有限责任公司 抗her3抗体、其制法及其应用
WO2016038610A1 (fr) 2014-09-08 2016-03-17 Yeda Research And Development Co. Ltd. Compositions et procédés de traitement d'un cancer résistant à un inhibiteur de la tyrosine kinase (tki)
WO2016038609A1 (fr) * 2014-09-08 2016-03-17 Yeda Research And Development Co. Ltd. Anticorps anti-her3 et leurs utilisations
US10184006B2 (en) 2015-06-04 2019-01-22 Merrimack Pharmaceuticals, Inc. Biomarkers for predicting outcomes of cancer therapy with ErbB3 inhibitors
EP3365373B1 (fr) 2015-10-23 2021-03-10 Merus N.V. Molécules de liaison inhibant la croissance de cancer
KR102905513B1 (ko) 2017-03-31 2026-01-02 메뤼스 엔.페. NRG1 융합 유전자를 가지는 세포를 치료하기 위한 ErbB-2 및 ErbB-3 결합 이중특이적 항체
JP7296891B2 (ja) 2017-05-17 2023-06-23 メルス ナムローゼ フェンノートシャップ 乳癌のためのＥｒｂＢ－２／ＥｒｂＢ－３二重特異性抗体と内分泌療法との組み合わせ
FI3665198T3 (fi) 2017-08-09 2025-04-25 Merus Nv EGFR:ää ja cMET:tä sitovia vasta-aineita
EP3665200B1 (fr) 2017-08-09 2025-04-16 University of Saskatchewan Agents de liaison à her3 et utilisations associées
GB201804094D0 (en) * 2018-03-14 2018-04-25 Ultrahuman Thirteen Ltd ERBB3 Binding agents
JP2021534811A (ja) * 2018-06-22 2021-12-16 シーアールディー ファーマシューティカルズ インコーポレイティド 抗ｈｅｒ３抗体およびその用途
KR20230086702A (ko) * 2020-10-14 2023-06-15 지앙수 헨그루이 파마슈티컬스 컴퍼니 리미티드 항-her3 항체 및 항-her3 항체-약물 접합체 및 이의 의학적 용도
EP4247430A4 (fr) * 2020-11-20 2024-12-11 Actinium Pharmaceuticals, Inc. Radioimmunothérapie de her3 pour le traitement de cancers solides
AU2022293634A1 (en) * 2021-06-15 2024-01-18 Beijing Sinotau Bio-Pharmaceuticals Technology Co., Ltd. Anti-her3 antibody, antibody drug conjugate containing the same, and use thereof
CN119013307A (zh) * 2022-04-13 2024-11-22 上海翰森生物医药科技有限公司 抗体或其抗原结合片段及其医药用途

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2631727T3 (es) * 2007-02-16 2017-09-04 Merrimack Pharmaceuticals, Inc. Anticuerpos contra el ErbB3 y usos de los mismos

Also Published As

Publication number Publication date
IL218097A0 (en) 2012-04-30
ZA201201195B (en) 2015-07-29
MX336091B (es) 2016-01-08
CA2771744A1 (fr) 2011-02-24
ECSP12011740A (es) 2013-02-28
EP2467164A2 (fr) 2012-06-27
KR20120059568A (ko) 2012-06-08
EA201200195A1 (ru) 2012-12-28
JP5752687B2 (ja) 2015-07-22
BR112012003809A2 (pt) 2019-09-24
WO2011022727A3 (fr) 2013-06-27
AU2010284018A1 (en) 2012-03-22
AU2010284018C1 (en) 2015-10-15
CR20120108A (es) 2012-06-05
CN103002912A (zh) 2013-03-27
WO2011022727A2 (fr) 2011-02-24
MX2012002172A (es) 2012-05-29
PE20121585A1 (es) 2012-11-29
AU2010284018B2 (en) 2014-06-05
SG178509A1 (en) 2012-04-27
NI201200027A (es) 2013-01-29
DOP2012000044A (es) 2012-06-30
TN2012000057A1 (en) 2013-09-19
JP2013506622A (ja) 2013-02-28
IN2012DN01518A (fr) 2015-06-05

Similar Documents

Publication Publication Date Title
MA33582B1 (fr) Anticorps contre l'ectodomaine de erbb3 et leurs utilisations
EA200901119A1 (ru) АНТИТЕЛА ПРОТИВ ErbB3 И ИХ ПРИМЕНЕНИЕ
CA3156451A1 (fr) Anticorps ayant une specificite pour la nectine -4 et leurs utilisations
PH12022551298A1 (en) Antibodies specific for cd47, pd-l1, and uses thereof
PH12019501115A1 (en) Anti-cd134 (ox40) antibodies and uses thereof
WO2020039321A8 (fr) Anticorps anti-gdf15, compositions et procédés d'utilisation
PH12015500248A1 (en) Humanized anti-cxcr5 antibodies, derivatives thereof and their uses
MA49038B1 (fr) Anticorps bispécifiques se liant particulièrement à pd1 et lag3
SA522431756B1 (ar) Tigit أجسام مضادة لـ
EP2560994A4 (fr) Anticorps anti-cd122
MA43186B1 (fr) Anticorps se liant spécifiquement à pd-1 et leurs utilisations
MX2019012953A (es) Anticuerpo biespecifico contra ox40 y ctla-4.
NZ591153A (en) Anti-cd5 antibodies
MA35740B1 (fr) Compositions et procédés pour des anticorps ciblant le facteur p
CL2012000254A1 (es) Anticuerpo aislado de unión a antígeno que se une a proteína atenuante de linfocitos b y t (btla); ácido nucleico que lo codifica; composición que comprende a dicho anticuerpo; y vector de expresión.
MX2010005031A (es) Anticuerpos de axl.
MX2011011825A (es) Anticuerpos humanizados para axl.
MX344971B (es) Anticuerpos anti-ctla4 humanizados.
MX369148B (es) Agentes de unión kir3dl2.
MA38828A1 (fr) Anticorps dirigés contre l'inhibiteur des activateurs du plasminogène de type 1 (pai-1) et leurs utilisations
EA202092448A1 (ru) Axl-специфичные антитела для лечения онкологических заболеваний
MA47221A1 (fr) Anticorps monoclonal à pd-l1
EP2493930A4 (fr) Compositions et méthodes pour le traitement de troubles inflammatoires
EA201291460A1 (ru) Олигобензамидные соединения и их применение
IN2014CN04374A (fr)